Introduction
Therapeutic research on psilocybin has undergone a renaissance since the early 2000s, following decades of regulatory restriction after the Controlled Substances Act of 1970. What began as small Phase I safety studies has rapidly expanded into well-powered Phase IIb randomised controlled trials involving hundreds of participants across multiple continents. The FDA granted psilocybin Breakthrough Therapy Designation for treatment-resistant depression in 2018 and for major depressive disorder (MDD) in 2019, significantly expediting the research and regulatory review process.
This guide synthesises the most significant published findings, describes the conditions under investigation, and explains the standard treatment protocol used across leading research institutions including Johns Hopkins University, Imperial College London, NYU Langone Health, and COMPASS Pathways.
Landmark Studies
Major Depressive Disorder (Davis et al., 2020)
A pivotal 2020 study published in JAMA Psychiatry by Alan Davis and colleagues at Johns Hopkins recruited 24 adults with MDD who were not on antidepressants. Participants received two psilocybin sessions (20mg/70kg and 30mg/70kg) two weeks apart, supported by preparation and integration therapy. At four-week follow-up, 71% of participants showed a clinically significant response (50% reduction in GRID-Hamilton Depression Rating Scale scores) and 54% met criteria for remission. Effect sizes were among the largest ever reported in depression research (Cohen's d > 2.0). A 12-month follow-up published in 2022 found the majority of responders maintained improvements.
Treatment-Resistant Depression vs SSRIs (Carhart-Harris et al., 2021)
The COMPASS-funded COMP006 study, published in the New England Journal of Medicine in 2021, was the first randomised controlled trial to directly compare psilocybin therapy with a leading SSRI (escitalopram) for treatment-resistant depression. Both groups showed similar reductions on the primary outcome (QIDS-SR16). However, psilocybin outperformed escitalopram on several secondary measures including emotional functioning, psychological wellbeing, anhedonia, and connectedness. The psilocybin group did not experience the blunted affect commonly reported with SSRIs.
COMPASS Phase IIb Trial (2022)
The largest psilocybin RCT published to date enrolled 233 patients with treatment-resistant depression across 22 sites in 10 countries. Participants received a single dose of COMP360 psilocybin (1mg, 10mg, or 25mg) alongside psychological support. The 25mg dose produced significantly greater reductions in MADRS depression scores at 3 weeks compared with the 1mg control (p=0.004), demonstrating a clear dose-dependent therapeutic response. Approximately 29% of the 25mg group achieved remission at 3 weeks. These results form the basis for the ongoing Phase III programme.
Tobacco Addiction (Johnson et al., 2014 & Follow-up)
Matthew Johnson and colleagues at Johns Hopkins conducted an open-label pilot study in 2014 examining psilocybin-facilitated tobacco cessation in 15 smokers. Participants received 2-3 high-dose psilocybin sessions alongside cognitive-behavioural therapy. At six-month follow-up, 80% of participants were biologically verified abstinent — a remarkable rate compared to standard cessation treatments (15-30%). A five-year follow-up published in 2017 found 67% sustained abstinence. A randomised controlled trial comparing psilocybin-assisted therapy to nicotine patch is currently ongoing.
Alcohol Use Disorder (Bogenschutz et al., 2022)
A 2022 RCT published in JAMA Psychiatry enrolled 93 adults with alcohol use disorder. Participants received either two psilocybin sessions or two diphenhydramine (active placebo) sessions, alongside motivational enhancement therapy. The psilocybin group showed significantly greater reductions in heavy drinking days in the 32 weeks after the first medication session (9.7% vs 23.6% heavy drinking days; p=0.0002), one of the strongest results for any pharmacological intervention in alcohol dependence.
End-of-Life Anxiety (Griffiths et al., 2016)
A randomised crossover trial by Griffiths and colleagues enrolled 51 cancer patients with life-threatening diagnoses and significant anxiety/depression. A single high-dose psilocybin session produced immediate, large, and sustained decreases in depression and anxiety, with 60-80% of participants classified as responders at six months. Outcomes generalised to quality of life and existential distress measures. These findings were replicated in a concurrent NYU trial by Ross et al. published simultaneously in the same journal.
How the Mystical Experience Predicts Outcome
A consistent finding across multiple research groups is that the magnitude of the mystical-type experience during the psilocybin session predicts long-term therapeutic outcomes. Roland Griffiths and colleagues at Hopkins used the validated Mystical Experience Questionnaire (MEQ30) to demonstrate this relationship. Participants who score above a threshold on the MEQ30 — characterised by unity, transcendence of time and space, noetic quality, and a sense of sacredness — show significantly greater and more durable therapeutic benefit. This finding has important implications for optimising set, setting, and dose.
Research on Neuroplasticity
A 2021 paper by Ly and colleagues in Cell Reports demonstrated that psilocin promotes rapid and sustained structural neuroplasticity in cortical neurons — including dendritic spine growth and synaptogenesis — at concentrations relevant to psychedelic doses. These changes occurred within 24 hours and persisted for at least one month in mouse models. Human neuroimaging data from Imperial College London showed lasting changes in amygdala reactivity and functional connectivity patterns following psilocybin treatment, consistent with a single session producing durable biological reorganisation.
Standard Therapeutic Protocol
Despite variation across research groups, most clinical psilocybin protocols share a common three-phase structure:
Preparation Phase (2-3 sessions)
Before any psilocybin is administered, participants meet with two trained guides or therapists for preparatory sessions. Goals include building therapeutic rapport, exploring personal history and intentions, addressing anticipatory anxiety, explaining what to expect, and developing a psychological framework for navigating challenging material. The preparation phase is considered critical — many researchers attribute a substantial portion of therapeutic benefit to the therapeutic relationship and expectation-setting that occurs here.
Dosing Session (6-8 hours)
The psilocybin session takes place in a specially designed room intended to feel warm and home-like rather than clinical. Participants typically lie on a couch with eyeshades and headphones playing a curated music programme. Two therapists remain present throughout. Participants are encouraged to "trust, let go, and be open" to whatever arises. Most clinical protocols use psilocybin doses of 25mg (synthetic, weight-adjusted) or the equivalent of approximately 3-5g of dried P. cubensis. Sessions last 6-8 hours from dosing to return to baseline.
Integration Phase (2-3 sessions)
In the days and weeks following the dosing session, participants return for integration therapy — sessions that help translate the insights and emotional material of the dosing session into lasting cognitive and behavioural changes. Integration is widely regarded as essential for durable outcomes. The psilocybin experience opens a window of psychological flexibility that integration work helps convert into sustained change. Practices encouraged include journaling, contemplative exercises, and continued therapeutic exploration.
Conditions Under Active Investigation
Beyond conditions with published RCT data, psilocybin is currently under investigation in registered clinical trials for:
- Post-traumatic stress disorder (PTSD) — Phase II trials underway at several US institutions
- Obsessive-compulsive disorder (OCD) — Building on positive pilot data from Francisco Moreno's 2006 study
- Anorexia nervosa — Early-phase trial at UCSF examining psilocybin's effects on cognitive flexibility
- Cluster headache and migraine — Phase II trials at Yale University
- Demoralization in chronic illness — Studies at Memorial Sloan Kettering
- Opioid use disorder — Emerging trial programmes examining psilocybin as an adjunct to medication-assisted treatment
Safety Profile in Clinical Research
Across hundreds of participants in clinical trials, psilocybin administered in supervised settings has shown a notably clean safety profile. No serious adverse events directly attributable to psilocybin pharmacology have been reported in the contemporary clinical research literature. Common adverse effects are transient anxiety, nausea (brief and onset-related), headache, and elevated blood pressure. Psychological adverse effects — including challenging experiences and transient paranoia — occur but are generally manageable within the supportive therapeutic container. No cases of persisting psychosis have been reported in screened populations. Careful psychiatric exclusion criteria (excluding individuals with personal or family history of schizophrenia or psychosis) are applied in all trials.
Regulatory Landscape
As of mid-2026, psilocybin remains a Schedule I controlled substance under US federal law. Oregon legalised supervised psilocybin services in 2020 (Measure 109, implemented 2023) and Colorado followed with Proposition 122 in 2022. In Australia, the TGA reclassified psilocybin as Schedule 8 effective July 2023, permitting authorised psychiatrists to prescribe it for treatment-resistant depression — making Australia the first country to formally regulate therapeutic psilocybin access. Regulatory approval in the EU and UK remains pending Phase III trial data.
Conclusion
The past decade of clinical research has established a credible, evidence-based rationale for psilocybin as a therapeutic intervention for several mental health conditions, particularly treatment-resistant depression, MDD, alcohol use disorder, end-of-life anxiety, and tobacco addiction. Effect sizes are large by psychiatric standards, therapeutic benefits appear durable, and the safety profile in screened populations is favourable. Ongoing Phase III trials will determine whether psilocybin achieves formal regulatory approval within this decade.
Note: This page is for educational purposes only. Psilocybin remains a controlled substance in most jurisdictions. None of the content here constitutes medical advice or encouragement to use psilocybin outside legally authorised contexts.